Journal article

Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression

Lana J Williams, Margaret J Henry, Michael Berk, Seetal Dodd, Felice N Jacka, Mark A Kotowicz, Geoffrey C Nicholson, Julie A Pasco

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2008

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are a first-line treatment for depression. They have been reported to regulate serotonin signalling in bone cells and may influence bone metabolism. This study aimed to investigate the effect of SSRIs on bone mineral density (BMD) in a sample of women with a lifetime history of depression. In this community-based study of 607 women, a history of depression was ascertained using the structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-TR research version, non-patient edition. BMD was measured at the posterior-anterior (PA) spine, hip, total body and forearm using dual energy absorptiometry, and medicat..

View full abstract